Heslin Kevin C, Owens Pamela L, Karaca Zeynal, Barrett Marguerite L, Moore Brian J, Elixhauser Anne
*Center for Delivery, Organization, and Markets, Agency for Healthcare Research and Quality, Rockville, MD †ML Barrett Inc., Del Mar, CA ‡IBM Watson Health, Ann Arbor, MI.
Med Care. 2017 Nov;55(11):918-923. doi: 10.1097/MLR.0000000000000805.
Trend analyses of opioid-related inpatient stays depend on the availability of comparable data over time. In October 2015, the US transitioned diagnosis coding from International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to ICD-10-CM, increasing from ∼14,000 to 68,000 codes. This study examines how trend analyses of inpatient stays involving opioid diagnoses were affected by the transition to ICD-10-CM.
Data are from Healthcare Cost and Utilization Project State Inpatient Databases for 14 states in 2015-2016, representing 26% of acute care inpatient discharges in the US.
We examined changes in the number of opioid-related stays before, during, and after the transition to ICD-10-CM using quarterly ICD-9-CM data from 2015 and quarterly ICD-10-CM data from the fourth quarter of 2015 and the first 3 quarters of 2016.
Overall, stays involving any opioid-related diagnosis increased by 14.1% during the ICD transition-which was preceded by a much lower 5.0% average quarterly increase before the transition and followed by a 3.5% average increase after the transition. In stratified analysis, stays involving adverse effects of opioids in therapeutic use showed the largest increase (63.2%) during the transition, whereas stays involving abuse and poisoning diagnoses decreased by 21.1% and 12.4%, respectively.
The sharp increase in opioid-related stays overall during the transition to ICD-10-CM may indicate that the new classification system is capturing stays that were missed by ICD-9-CM data. Estimates of stays involving other diagnoses may also be affected, and analysts should assess potential discontinuities in trends across the ICD transition.
阿片类药物相关住院时间的趋势分析取决于随时间可得的可比数据。2015年10月,美国将诊断编码从《国际疾病分类,第九版,临床修订本》(ICD-9-CM)转换为ICD-10-CM,编码数量从约14000个增加到68000个。本研究探讨了向ICD-10-CM转换对涉及阿片类药物诊断的住院时间趋势分析的影响。
数据来自2015 - 2016年14个州的医疗成本和利用项目州住院数据库,占美国急性护理住院出院人数的26%。
我们使用2015年的季度ICD-9-CM数据以及2015年第四季度和2016年前三个季度的季度ICD-10-CM数据,研究了向ICD-10-CM转换之前、期间和之后与阿片类药物相关住院时间的变化。
总体而言,在ICD转换期间,涉及任何阿片类药物相关诊断的住院时间增加了14.1%,在转换之前平均季度增长率低得多,为5.0%,转换之后平均增长率为3.5%。在分层分析中,涉及治疗用阿片类药物不良反应的住院时间在转换期间增加幅度最大(63.2%),而涉及滥用和中毒诊断的住院时间分别减少了21.1%和12.4%。
向ICD-10-CM转换期间阿片类药物相关住院时间总体大幅增加,这可能表明新的分类系统捕捉到了ICD-9-CM数据遗漏的住院情况。涉及其他诊断的住院时间估计也可能受到影响,分析人员应评估ICD转换期间趋势的潜在不连续性。